Amarin Corp. Plc (AMRN)
11.79
+0.19
(+1.64%)
USD |
NASDAQ |
Oct 23, 16:00
11.83
+0.04
(+0.34%)
After-Hours: 20:00
Amarin Enterprise Value : -61.98M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -61.98M |
| October 22, 2026 | -65.97M |
| October 21, 2026 | -67.86M |
| October 20, 2026 | -68.49M |
| October 19, 2026 | -67.44M |
| October 16, 2026 | -71.85M |
| October 15, 2026 | -66.60M |
| October 14, 2026 | -65.76M |
| October 13, 2026 | -66.39M |
| October 12, 2026 | -67.44M |
| October 09, 2026 | -56.94M |
| October 08, 2026 | -57.78M |
| October 07, 2026 | -57.15M |
| October 06, 2026 | -56.10M |
| October 05, 2026 | -55.68M |
| October 02, 2026 | -50.22M |
| October 01, 2026 | -42.45M |
| September 30, 2026 | -36.57M |
| September 29, 2026 | -33.63M |
| September 28, 2026 | -31.32M |
| September 25, 2026 | -32.37M |
| September 24, 2026 | -27.54M |
| September 23, 2026 | -21.44M |
| September 22, 2026 | -20.81M |
| September 21, 2026 | -26.49M |
| Date | Value |
|---|---|
| September 18, 2026 | -23.34M |
| September 17, 2026 | -18.29M |
| September 16, 2026 | -18.92M |
| September 15, 2026 | -17.03M |
| September 14, 2026 | -15.56M |
| September 11, 2026 | -19.76M |
| September 10, 2026 | -14.72M |
| September 09, 2026 | -7.373M |
| September 08, 2026 | -10.31M |
| September 04, 2026 | -23.34M |
| September 03, 2026 | -21.65M |
| September 02, 2026 | -21.86M |
| September 01, 2026 | -18.82M |
| August 31, 2026 | -18.08M |
| August 28, 2026 | -16.19M |
| August 27, 2026 | -14.09M |
| August 26, 2026 | -7.688M |
| August 25, 2026 | -12.41M |
| August 24, 2026 | -18.92M |
| August 21, 2026 | -13.67M |
| August 20, 2026 | -14.30M |
| August 19, 2026 | -7.583M |
| August 18, 2026 | -12.83M |
| August 17, 2026 | -15.35M |
| August 14, 2026 | -14.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alkermes Plc | 8.226B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Akari Therapeutics Plc | 7.336M |
| Aldeyra Therapeutics, Inc. | -5.756M |
| DBV Technologies SA | 364.13M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.664M |
| Revenue (Quarterly) | 42.29M |
| Total Expenses (Quarterly) | 49.95M |
| EPS Diluted (Quarterly) | -0.3681 |
| Gross Profit Margin (Quarterly) | 34.00% |
| Profit Margin (Quarterly) | -18.12% |
| Earnings Yield | -11.01% |
| Normalized Earnings Yield | -6.226 |